Compare S&P Global Inc (SPGI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs TG Therapeutics Inc — how do they compare? S&P Global Inc trades at $419.2 (market cap $126.56B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: S&P Global Inc is far larger — about 14.8× TG Therapeutics Inc's market cap, and S&P Global Inc pays a 0.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SPGI | TGTX | |
|---|---|---|
Market Cap | $126.56B | $8.53B |
Sector | Financials | Health |
52-Week High | $522.21 | $59.06 |
52-Week Low | $370.42 | $26.94 |
Enterprise Value | $138.05B | $8.74B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPGI trades at $429.31, down 3.2% over 24h, with a bullish technical signal and strong fundamentals including a 30.54% net income margin and consistent earnings beats. Recent news highlights strategic acquisitions and a focus on AI-resistant businesses, while analyst consensus remains strongly positive with an 85.7% buy rating.
Outlook is favorable due to high profitability and growth initiatives, but risks include rising debt levels and market sensitivity. The stock offers upside to the $523.20 consensus target, supported by institutional interest and dividend consistency.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
